Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and marketing medical treatments. The company focuses on addressing various diseases across the United States and China. A key part of its pipeline involves voclosporin, an investigational compound being developed to treat conditions such as lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. Aurinia's primary operations are based out of Victoria, Canada.